TGFBR2 and cervical cancer: Our results suggest a possibility that simultaneous application of TGFBR2 agonist and hTERT inhibitors may be developed as a therapeutic strategy for treating cervical cancer, especially in the patients with TGFBR2low/hTERThigh expressions.